We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
NUBEQA (Bayer Australia Ltd)
Product name
NUBEQA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
182 working days (255)
Active ingredients
darolutamide
Registration type
NCE/NBE
Indication
NUBEQA (tablets) is indicated for the treatment of patients with non-metastatic castration resistant prostate cancer (nmCRPC).